Nilotinib: Optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib

Medicine and Dentistry

• Abelson Kinase 10%
• Age 10%
• Chronic Myelogenous Leukemia 80%
• Combination Therapy 40%
• Dasatinib 10%
• Development 10%
• Disease 10%
• Diseases 20%
• Enalapril Maleate 10%
• Gene Fusion 10%
• Imatinib 100%
• Inpatient 30%
• Mutant 10%
• Nilotinib 40%
• Patient 50%
• Phosphotransferase 10%
• Phosphotransferase Inhibitor 10%
• Point Mutation 10%
• Stem Cell 10%
• Survival 10%
• Tyrosine-Kinase Inhibitor 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Abelson Kinase 10%
• Chronic Myeloid Leukemia 80%
• Dasatinib 10%
• Diseases 20%
• Enalapril Maleate 10%
• Imatinib 100%
• Nilotinib 40%
• Phosphotransferase 10%
• Phosphotransferase Inhibitor 10%
• Protein Tyrosine Kinase Inhibitor 10%
• Survival 10%